Dataset Information

FFPE LFQ proteomics of Human Cerebral Development and CMV Encephalitis Fetal Brains

ABSTRACT: We utilize a rapid shotgun FFPE LFQ MS method to profile four regions of developing human cerebrum. Regions encompass neural precursor rich ventricular zones as well as intermediate and subplate and cortex regions accross human development from gestational weeks 16-36. Proteome signatures of the four fetal brain regions were determined using statistical tests and CMV-infected fetal brain encephalitis was analyzed to determine the region-specific effects of this neurodevelopmental disorder.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

SUBMITTER: Ugljesa Djuric

LAB HEAD: Eleftherios Diamandis

PROVIDER: PXD005065 | Pride | 2017-07-14

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 22

Publications

Spatiotemporal Proteomic Profiling of Human Cerebral Development.

Djuric Ugljesa U Rodrigues Deivid C DC Batruch Ihor I Ellis James J Shannon Patrick P Diamandis Phedias P

Molecular & cellular proteomics : MCP 20170707 9

Mass spectrometry (MS) analysis of human post-mortem central nervous system (CNS) tissue and induced pluripotent stem cell (iPSC)-based directed differentiations offer complementary avenues to define protein signatures of neurodevelopment. Methodological improvements of formalin-fixed, paraffin-embedded (FFPE) protein isolation now enable widespread proteomic analysis of well-annotated archival tissue samples in the context of development and disease. Here, we utilize a shotgun label-free quanti ...[more]

PMID: 28687556

Similar Datasets

Project description:Background: Congenital cytomegalovirus (cCMV) is a common intrauterine infection, leading to neurodevelopmental disabilities. Early prognostic assessment of the severity of cCMV has remained an ongoing challenge. We aimed to identify amniotic fluid biomarkers of the severity of cCMV-related fetal brain injury. Methods: Global proteome analysis was performed in mid-gestation amniotic fluid samples, comparing fetuses with severe cCMV to asymptomatic CMV-infected fetuses (the discovery cohort). The levels of selected differentially-excreted proteins were further determined by specific immunoassays, and evaluated in an independent validation cohort, including clinically-blinded amniotic fluid of CMV-infected fetuses from unrelated centers. Findings: Proteome analysis identified 29 amniotic fluid proteins with distinct abundance in fetuses with severe-, compared to asymptomatic, cCMV. Pathway analysis of the differentially-excreted proteins revealed enriched pathways of inflammatory response, cellular compromise, immunological disease, organismal injury, and neurological disease, underlining a link between excessive inflammation at the maternal-fetal interface and the development of cCMV-related fetal brain damage. Importantly, the levels of two of these proteins, chemerin and galectin-3-binding protein (Gal-3BP), selected for validation, demonstrated 88.2% sensitivity (each), 100-96.2% specificity, 100-93.8% positive predictive value, and 92.9-92.6% negative predictive value, with 0.98-0.97 area under the curve (for chemerin - Gal-3BP, respectively) in differentiating 17 fetuses with severe cCMV from 26 asymptomatic CMV-infected fetuses. Interpretation: These results identify the immunomodulatory proteins chemerin and Gal-3BP as new highly predictive amniotic fluid biomarkers of cCMV severity, which could guide early prognostic stratification and potential personalized treatment of cCMV-infected fetuses. Funding: Israel Science Foundation; Research Fund of the Hadassah Medical Organization

			Action	DRS
	CMV1_Cx.raw	Raw
	CMV1_IZ.raw	Raw
	CMV1_VZ.raw	Raw
	CMV2_Cx.raw	Raw
	CMV2_IZ.raw	Raw